Physician profile
Luke Canada
NPI 1437574696
$2,367.92
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,355 · 2022: $13.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.00 | 2021 | |
| Amarin Pharma, INC. | $222.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $186.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $143.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.16 | 2021 | |
| Pfizer INC. | $128.33 | 2021 | |
| Lilly USA, LLC | $123.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $116.44 | 2021 | |
| Astellas Pharma US INC | $92.98 | 2021 | |
| Glaxosmithkline, LLC. | $87.89 | 2021 | |
| Adlon Therapeutics L.P. | $74.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.06 | 2021 | |
| Novo Nordisk INC | $66.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $63.47 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.79 | 2021 | |
| Currax Pharmaceuticals LLC | $52.81 | 2021 | |
| Esperion Therapeutics, INC. | $43.07 | 2021 | |
| Dexcom, INC. | $33.17 | 2021 | |
| Ironwood Pharmaceuticals, INC | $30.03 | 2021 | |
| Cmp Pharma, INC. | $29.80 | 2021 | |
| Optinose US, INC. | $22.97 | 2021 | |
| Bausch Health US, LLC | $20.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.03 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.68 | 2021 | |
| Lundbeck LLC | $15.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.01 | 2021 | |
| Zealand Pharma US, INC. | $14.89 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.52 | 2021 | |
| Merck Sharp & Dohme LLC | $14.36 | 2021 | |
| Eisai INC. | $13.98 | 2021 | |
| Abbott Laboratories | $13.32 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Canada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.